EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Sparsentan: a dual endothelin and angiotensin II receptor antagonist approved for IgA nephropathy

Gates B Colbert iD, Hector M Madariaga, Anna Gaddy, Mohamed E Elrggal, Edgar V Lerma

Expert Review of Clinical Pharmacology · 03.07.2025 · 18 (7) · 441-448

DOI: 10.1080/17512433.2025.2532659 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 16.07.2025. Verfasst von Gates B Colbert und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Texas A&M University College of Medicine at Dallas, Dallas, TX, USA. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Angiotensin Receptor Antagonists, Endothelin Receptor Antagonists. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: IgA nephropathy (IgAN) is the most common primary glomerulonephritis. For decades, the only medication treatments that were widely accepted were the use of renin-angiotensin aldosterone inhibitors and corticosteroids. The early 2020s have brought a flurry of new treatments to the once dark IgA treatment landscape. Sparsentan is a novel dual-endothelin angiotensin receptor antagonist that has been approved as an add-on therapy for the treatment of IgAN. AREAS COVERED: We discuss the treatment landscape and the unmet needs for treating IgA nephropathy. Multiple clinical trials showing the efficacy of sparsentan including DUET, PROTECT, SPARTACUS, and SPARTAN will be described. Additionally, we will preview the future options for IgA patients. EXPERT OPINION: Sparsentan is a major step forward in improving outcomes for patients with IgAN. This once-a-day agent, in addition to other standards of care, limits proteinuria and progression to ESKD and kidney transplantation. The ability to lower proteinuria without weakening the immune system is a substantial gain for patients. As an agent that impacts the glomeruli directly, sparsentan is able to limit damage in mechanisms that previous RASi and steroids have not. Including sparsentan in the combination treatment for IgAN must be considered for adequate kidney protection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGAAngiotensin Receptor AntagonistsEndothelin Receptor AntagonistsHumansDisease ProgressionProteinuriaAnimals

Stichwörter der Autor:innen

Endothelin antagonistIgA nephropathychronic kidney diseaseglomerulonephritisproteinuriasparsentan

Substanzen

Angiotensin Receptor AntagonistsEndothelin Receptor Antagonists

Autor:innen und Institutionen

  • Division of Nephrology, Texas A&M University College of Medicine at Dallas, Dallas, TX, USA.
  • Department of Surgery, Abdominal Transplant Institute, Tufts Medical Center, Boston, MA, USA.
  • Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Division of Nephrology, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
  • Section of Nephrology, University of Illinois at Chicago, Chicago, IL, USA.
  • Division of Nephrology, Associates in Nephrology, Chicago, IL, USA.

ORCID-Profile: Gates B Colbert

Zitieren

APA

Colbert, G. B., Madariaga, H. M., Gaddy, A., Elrggal, M. E., & Lerma, E. V. (2025). Sparsentan: a dual endothelin and angiotensin II receptor antagonist approved for IgA nephropathy. Expert Review of Clinical Pharmacology, 18(7), 441-448. https://doi.org/10.1080/17512433.2025.2532659

Vancouver

Colbert GB, Madariaga HM, Gaddy A, Elrggal ME, Lerma EV. Sparsentan: a dual endothelin and angiotensin II receptor antagonist approved for IgA nephropathy. Expert Review of Clinical Pharmacology. 2025;18(7):441-448. doi:10.1080/17512433.2025.2532659

BibTeX
@article{Colbert2025,
  author = {Colbert, Gates B and Madariaga, Hector M and Gaddy, Anna and Elrggal, Mohamed E and Lerma, Edgar V},
  title = {Sparsentan: a dual endothelin and angiotensin II receptor antagonist approved for IgA nephropathy},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2025},
  volume = {18},
  number = {7},
  pages = {441--448},
  doi = {10.1080/17512433.2025.2532659}
}
Kostenlos starten →